Regen BioPharma (RGBPP) Receivables - Net (2016 - 2025)
Regen BioPharma (RGBPP) has disclosed Receivables - Net for 11 consecutive years, with $232298.0 as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Net rose 89.94% to $232298.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $232298.0, a 89.94% increase, with the full-year FY2025 number at $204873.0, up 115.94% from a year prior.
- Receivables - Net was $232298.0 for Q4 2025 at Regen BioPharma, up from $204873.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $295466.0 in Q2 2022 to a low of $12298.0 in Q4 2023.
- A 5-year average of $156991.9 and a median of $158042.0 in 2021 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: plummeted 90.66% in 2023, then skyrocketed 894.45% in 2024.
- Regen BioPharma's Receivables - Net stood at $240617.0 in 2021, then plummeted by 45.27% to $131698.0 in 2022, then tumbled by 90.66% to $12298.0 in 2023, then surged by 894.45% to $122298.0 in 2024, then soared by 89.94% to $232298.0 in 2025.
- Per Business Quant, the three most recent readings for RGBPP's Receivables - Net are $232298.0 (Q4 2025), $204873.0 (Q3 2025), and $177147.0 (Q2 2025).